Osteoarthritis: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PI3K 0
• NRF2 0
• NLRP3 0
• MAPK 0
• AMPK 1
• GLP-1 3
• IL-1 1
• AKT 0
• mTOR 0
• STAT3 0
• SIRT1 0
• TLR4 0
• JAK 0
• COX-2 0
• ERK 0
• CTNNB1 0
• IL-6 0
• PPAR 0
• STING 0
• TP53 0
• GPX4 0
• HIF-1 0
• JNK 0
• TNF 0
• YAP 0
• PINK1 0
• PTEN 0
• VEGF 0
• IL-17 0
• METTL3 0
• RANKL 0
• EGFR 0
• BCL-2 0
• CXCR4 0
• FTO 0
• HMGB1 0
• MMP-9 0
• SGLT2 1
• CGRP 0
• FGFR 0
• HDAC 0
• KEAP1 0
• MDM2 0
• PARP 0
• APOE 0
• BRD4 0
• CDK4/6 0
• ESR1 0
• FAK 0
• GIP 0
• HER2 0
• HSP90 0
• MEK 0
• NMDA 0
• TREM2 0
• APP 0
• AR 0
• ARID1A 0
• CD47 0
• CFTR 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIA · F30

  Dissecting Age-related Changes in Stem Cell-based Bone-Gut Crosstalk

  University of California at Davis· Davis, United States· US$43,752 awarded in fiscal year 2026· until Sept 2029

• NIH NINDS · R43

  Development of an Anti-Nerve Growth Factor Active Immunotherapy for Difficult-to-Manage Pain

  Twilight Bioscience, Inc.· Topsfield, United States· US$350,188 awarded in fiscal year 2026· until Aug 2028

• NIH NIAMS · R56

  Understanding the Roles of Synovitis, Knee-Adjacent Obesity and Sarcopenia in Pain Phenotypes and Structural Progression of Knee Osteoarthritis - An Analysis of the Entire Osteoarthritis Initiative

  University of California, San Francisco· San Francisco, United States· US$620,656 awarded in fiscal year 2026· until Aug 2027

• NIH NIAMS · R01

  Fe Metabolism Compromises Articular Chondrocytes during Joint Degeneration

  University of Iowa· Iowa City, United States· US$660,873 awarded in fiscal year 2026· until Aug 2031

• NIH NIDCR · R43

  SN102: a Novel Gene Therapy for Trigeminal Neuralgia Pain

  Sereneuro Therapeutics, Inc.· Baltimore, United States· US$338,115 awarded in fiscal year 2026· until Sept 2027

• European Commission (Horizon Europe) · HORIZON-ERC

  Biofabrication of gene activated grafts targeting synovial joint inflammation and meniscus repair (SMART-MENISCUS)

  The Provost, Fellows, Foundation Scholars & the Other Members of Board, of the College of the Holy & Undivided Trinity of Queen Elizabeth Near Dublin· Dublin, Ireland· EU contribution €1,500,000· until Jan 2032

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  EV-enriched secretome from cord blood as a new disease modifying treatment for osteoarthritis (ExoCordOA)

  Exogenus Therapeutics Sa· Cantanhede, Portugal· EU contribution €13,000,000· until Aug 2031· 3 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Smart Platforms for Osteochondral Regeneration through on-demand Activation (SPORA)

  Instituto Superior Tecnico· Lisboa, Portugal· EU contribution €191,343· until Aug 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Newly engineered lignin nanocarrier for curcumin delivery to tackle inflammation and limited synovial drug residence in osteoarthritis (LigNPsCURCDeLIV)

  University of Leeds· Leeds, United Kingdom· EU contribution €276,188· until Sept 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Gene-activated tri-layer 3D-bioprinted scaffold for enhanced osteochondral defect repair (GATSO-3D)

  Royal College of Surgeons in Ireland· Dublin 2, Ireland· EU contribution €252,729· until Jul 2028

  The disease is named only in the funder's project summary, not in the title.

10 of 488 running projects, newest first. Listed amounts together: US$275.7m + €106.0m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 43
• Organoids 4
• Mendelian Randomization Analysis 56
• CRISPR-Cas Systems 1
• Gene Expression Profiling 106
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 3
• Exome Sequencing 1
• Proteomics 43
• Metabolomics 26
• Mass Spectrometry 5
• Flow Cytometry 7
• Immunohistochemistry 19
• Positron-Emission Tomography 6
• Magnetic Resonance Imaging 276
• Machine Learning 78
• Deep Learning 45
• Cohort Studies 148
• Genome-Wide Association Study 48

• Somatic mutation profiles in aged military nuclear test veterans: A comparative whole-genome sequence study.

  PLoS One, Jun 2026

• Comparative whole-genome analyses of articular chondrocytes and skin fibroblasts reveal distinct genome instability landscapes in mesenchymal cell types.

  PLoS Genet, May 2026

• Single-cell analysis of the somatic mutational landscape in human chondrocytes during aging and in osteoarthritis.

  Nat Aging, Nov 2025

See which targets of this disease your abstract mentions, and go to the people working on them.